Evidence map›Paper›PMID 40708169›Full record

ArticleHuman vaccines & immunotherapeutics2025

Bibliometric analysis of global research trends in pancreatic cancer immunotherapy.

Tong Fu, Yuqing Chen, Hao Wang, Linlin He, Jian Zhang, Yongping Zhou, Xuchu Duan, Xu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tong FuDepartment of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
Yuqing ChenDepartment of Pharmacy, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Hao WangDepartment of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Jiangnan University, Wuxi, China.
Linlin HeDepartment of Pharmacy, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Jian ZhangMathematics Research Group, Ordos City No. 2 Middle School, Ordos, China.
Yongping ZhouDepartment of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Jiangnan University, Wuxi, China.
Xuchu DuanSchool of Life Science, Nantong Laboratory of Development and Diseases, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.
Xu ZhangClinical Medical Research Center, Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Affiliated Wuxi Clinical College of Nantong University, The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Jiangnan University, Wuxi, China.ORCID 0009-0008-2672-6260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a highly malignant tumor with poor prognosis and limited treatments. Immunotherapy shows promise in improving outcomes, but bibliometric analyses in this field are scarce. Our work reveals emerging trends, identifies research gaps, and highlights shifts in focus, offering valuable guidance for future research of immunotherapy and clinical practice. Pancreatic cancer immunotherapy bibliometric analyses were performed utilizing tools such as CiteSpace, VOSviewer, and RStudio, with a focus on the temporal and spatial distribution, prominent authors, research themes, keywords, and citation networks. The analysis reveals a significant increase in research activity on pancreatic cancer immunotherapy over the past decade, with hotspots including ICIs, CAR-T therapy, novel biomarkers, targeted therapies, the tumor microenvironment, and personalized treatment strategies. This study systematically reviews pancreatic cancer immunotherapy research progress from 1991 to 2024, highlighting key hotspots and trends. Future efforts should focus on ICIs, CAR-T therapy, and combination strategies, to enhance outcomes and extend patient survival.

Indexed as

BibliometricsBiomedical ResearchImmunotherapyPancreatic NeoplasmsHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmune Checkpoint Inhibitorshotspots and trendsimmunotherapyPancreatic cancertherapytreatment strategies

Identifiers

PMID40708169
PMCPMC12309542

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.